Should You Buy, Hold or Sell Abbott Stock Post-Q3 Earnings?
Should You Buy, Hold or Sell Abbott Stock Post-Q3 Earnings? TradingView
Covered in this story
Analyst targets on Abbott Laboratories
- BTIG: at $103 · target $125 by Oct 2027 · Buy via Investing.com
- Mizuho: at $103 · target $115 by Oct 2027 · Neutral via Investing.com
- StoneX: at $103 · target $120 by Oct 2027 · Buy via Investing.com
“At” is the closing price nearest the day the target was reported, the price we score it from; it is not an earlier target. Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $ABT yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Abbott Laboratories →Dalsna Finance is currently tracking 36 stories mentioning Abbott Laboratories, the earliest published 6 May 2017.
Summary aggregated from TradingView's public RSS feed. The full reporting belongs to TradingView — please read it on their site.